Results 121 to 130 of about 22,142 (188)

Cardiovascular Toxicity of BTK Inhibitors: A Patient-Centered Framework for Risk Stratification and Management. [PDF]

J Clin Med
Tedeschi A, Barocelli F, Gerra L, Breviario F, Sbarra F, Pagnoni G, Marasacchia G, Marangi F, Darroudi S, Di Spigno F, Coppi F, Arcari A, Losi G, Vallisa D, Niccoli G, Aschieri D, Navazio A, Tarantini L.   +17 more
europepmc   +1 more source

Correction to: DLBCL-microenvironment interactions: cytokine profiling and ECM mediated ibrutinib resistance in a 3D bone-based model. [PDF]

Med Oncol
Ceccato J, Piazza M, Gualtiero G, Carraro S, Cinetto F, Biz C, Manni S, Pizzi M, Pianalto S, Zoletto S, Carabotta V, Danesin N, Ruggieri P, Dei Tos AP, Piazza F, Trentin L, Vianello F.   +16 more
europepmc   +1 more source

Longitudinal changes in left atrial function during chronic ibrutinib therapy: a prospective observational study. [PDF]

Front Cardiovasc Med
Kolacevic Zeljkovic M, Basic-Kinda S, Čaržavec D, Vodanovic M, Mandac Smoljanovic I, Jaksic O, Novak M, Ostojic-Kolonic S, Dujmovic D, Pejsa V, Aurer I, Bulj N.   +11 more
europepmc   +1 more source

Novel targeted therapies for central nervous system involvement in chronic lymphocytic leukemia: A systematic review. [PDF]

Ther Adv Hematol
Al-Mashdali AF, Abdelraof MO, Mukhtar RM, Mohamed SF.   +3 more
europepmc   +1 more source

Trials in progress: CARMAN - study protocol of a randomized controlled, international, multicenter, open-label phase II trial evaluating early treatment intensification in patients with high-risk mantle cell lymphoma using CAR-T-cell treatment after an abbreviated induction therapy with rituximab and ibrutinib and 6 months ibrutinib maintenance as compared to standard of care induction and maintenance. [PDF]

BMC Cancer
Tilch MK, Schmidt C, Trneny M, Giné E, Hermine O, Ohler A, Herold S, Hoster E, Jiang L, Pott C, Dreyling M, Hess G.   +11 more
europepmc   +1 more source

Acquired Amegakaryocytic Thrombocytopenia Presenting as Pancytopenia in a Patient With Chronic Lymphocytic Leukemia: A Case Report. [PDF]

Case Rep Hematol
Chen CC, Shah A, Andrawis M, Benjamin J, Shah M, Fratella-Calabrese A, Chang VT.   +6 more
europepmc   +1 more source

Ibrutinib plus venetoclax for relapsed/refractory mantle cell lymphoma: Final analysis of the phase 3 SYMPATICO study. [PDF]

Br J Haematol
Wang M, Jurczak W, Trneny M, Belada D, Wrobel T, Ghosh N, Keating MM, van Meerten T, Alvarez RF, von Keudell G, Thieblemont C, Peyrade F, Andre M, Hoffmann M, Szafer-Glusman E, Lin J, Dean JP, Neuenburg JK, Tam CS.   +18 more
europepmc   +1 more source

A Phase I/II Study of Ibrutinib Plus Trastuzumab in HER2-Positive Metastatic Breast Cancer. [PDF]

Cancer Med
O'Shaughnessy J, Glidden A, Locke T, Scales A, Gatewood E, Blanck JP, Castaneda-Gill J, Patel S, Mahnke YD, Wang X, Blas P.   +10 more
europepmc   +1 more source

The place of acalabrutinib-obinutuzumab combination in the first-line treatment of patients with chronic lymphocytic leukemia. [PDF]

Transl Cancer Res
Szymczyk A, Hus I.
europepmc   +1 more source

Sequencing asymmetry: the case for caution before first-line pirtobrutinib in chronic lymphocytic leukemia. [PDF]

Ann Hematol
Chen B, Qian S.
europepmc   +1 more source